Shares of Immune Design Corp. (NASDAQ:IMDZ) have been given an average rating of “Buy” by the six analysts that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $16.33.

A number of analysts have recently issued reports on the company. BidaskClub cut Immune Design Corp. from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 5th. ValuEngine raised Immune Design Corp. from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. Zacks Investment Research raised Immune Design Corp. from a “hold” rating to a “buy” rating and set a $11.00 price objective for the company in a research report on Tuesday, July 18th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Immune Design Corp. in a research report on Wednesday, June 28th. Finally, Royal Bank Of Canada assumed coverage on Immune Design Corp. in a research report on Thursday. They issued an “outperform” rating and a $20.00 price objective for the company.

Immune Design Corp. (IMDZ) traded up 0.54% on Thursday, reaching $9.35. 408,203 shares of the company’s stock were exchanged. The stock’s market capitalization is $239.55 million. Immune Design Corp. has a 1-year low of $4.50 and a 1-year high of $13.05. The firm’s 50 day moving average is $9.69 and its 200 day moving average is $7.90.

Immune Design Corp. (NASDAQ:IMDZ) last released its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.65) by $0.11. Immune Design Corp. had a negative return on equity of 59.14% and a negative net margin of 324.33%. The company had revenue of $0.73 million during the quarter, compared to analysts’ expectations of $1.50 million. Analysts expect that Immune Design Corp. will post ($2.34) EPS for the current year.

In other Immune Design Corp. news, insider Wayne Gombotz sold 10,000 shares of the firm’s stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $11.43, for a total transaction of $114,300.00. Following the transaction, the insider now owns 33,054 shares in the company, valued at approximately $377,807.22. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Lewis W. Coleman acquired 8,000 shares of the stock in a transaction on Friday, July 7th. The shares were bought at an average price of $9.27 per share, for a total transaction of $74,160.00. Following the purchase, the director now owns 40,000 shares in the company, valued at $370,800. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 30,000 shares of company stock worth $272,760. Corporate insiders own 42.90% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the company. Renaissance Technologies LLC increased its stake in shares of Immune Design Corp. by 170.0% in the 1st quarter. Renaissance Technologies LLC now owns 111,740 shares of the biotechnology company’s stock valued at $760,000 after purchasing an additional 70,351 shares during the last quarter. Victory Capital Management Inc. increased its stake in shares of Immune Design Corp. by 2.1% in the 2nd quarter. Victory Capital Management Inc. now owns 1,977,564 shares of the biotechnology company’s stock valued at $19,281,000 after purchasing an additional 40,010 shares during the last quarter. Trexquant Investment LP bought a new position in shares of Immune Design Corp. in the 1st quarter valued at $183,000. Wells Fargo & Company MN increased its stake in shares of Immune Design Corp. by 46.5% in the 1st quarter. Wells Fargo & Company MN now owns 148,887 shares of the biotechnology company’s stock valued at $1,012,000 after purchasing an additional 47,266 shares during the last quarter. Finally, Personal Capital Advisors Corp bought a new position in shares of Immune Design Corp. in the 2nd quarter valued at $356,000. Institutional investors own 51.46% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Analysts Set Immune Design Corp. (IMDZ) Target Price at $14.50” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.thecerbatgem.com/2017/09/17/analysts-set-immune-design-corp-imdz-target-price-at-14-50.html.

About Immune Design Corp.

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Receive News & Stock Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related stocks with our FREE daily email newsletter.